Advani et al. [241] reported that the CD47-blocking antibody Hu5F9-G4 had therapeutic efficacy in combination with rituximab in patients with diffuse large B-cell lymphoma and follicular lymphoma, and the authors proposed that blocking CD47–SIRPα interactions improved tumor cell phagocytosis by macrophages [241]. The gene discussed is SIRPA; the disease is neoplasm.